Danaher Corporation $DHR Shares Newly Bought by Dickmeyer Boyce Financial Management Inc.

Dickmeyer Boyce Financial Management Inc. acquired a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 7,673 shares of the conglomerate’s stock, valued at approximately $1,700,000. Danaher accounts for approximately 0.8% of Dickmeyer Boyce Financial Management Inc.’s holdings, making the stock its 29th largest position.

A number of other hedge funds have also added to or reduced their stakes in DHR. BlackRock Inc. bought a new stake in shares of Danaher during the second quarter valued at approximately $10,492,520,000. Jupiter Topco LLC purchased a new position in Danaher during the 2nd quarter worth $1,456,317,000. Generation Investment Management LLP purchased a new stake in shares of Danaher in the 2nd quarter worth $1,287,949,000. Bank of America Corp DE purchased a new position in shares of Danaher during the second quarter valued at $993,846,000. Finally, Legal & General Group Plc bought a new stake in shares of Danaher in the second quarter valued at about $801,056,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on DHR. UBS Group assumed coverage on shares of Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. The Goldman Sachs Group upped their price target on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Barclays lifted their price objective on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday. Evercore reissued an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average target price of $235.23.

Danaher Stock Down 1.6%

Shares of Danaher stock traded down $3.52 on Thursday, reaching $214.97. The stock had a trading volume of 3,088,188 shares, compared to its average volume of 4,451,466. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a 50 day moving average price of $210.46 and a 200 day moving average price of $194.25. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $151.12 billion, a P/E ratio of 38.18, a P/E/G ratio of 2.68 and a beta of 0.76.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue was up 5.5% compared to the same quarter last year. During the same period last year, the firm earned $0.77 earnings per share. As a group, equities research analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.